Evidence map›Paper›PMID 32838309›Full record

ArticleThe Lancet. Rheumatology2020

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.

Jixin Zhong, Guifen Shen, Huiqin Yang, Anbin Huang, Xiaoqi Chen, Li Dong, Bin Wu, Anbin Zhang, Linchong Su, Xiaoqiang Hou and 10 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Jixin ZhongDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Guifen ShenDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Huiqin YangDepartment of Rheumatology and Immunology, Wuhan No.1 Hospital, Wuhan, Hubei, China.
Anbin HuangDepartment of Rheumatology and Immunology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xiaoqi ChenDepartment of Rheumatology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Li DongDepartment of Rheumatology and Immunology, Jingzhou City Central Hospital of Hubei Province, Jingzhou, Hubei, China.
Bin WuDepartment of Rheumatology and Immunology, The First People's Hospital of Jingzhou, Jingzhou, Hubei, China.
Anbin ZhangDepartment of Rheumatology and Immunology, Xiangyang Central Hospital, Xiangyang, Hubei, China.
Linchong SuDepartment of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, Enshi, China.
Xiaoqiang HouThe First College of Clinical Medical Sciences, China Three Gorges University, Yichang, Hubei, China.
Shulin SongDepartment of Rheumatology and Immunology, The First People's Hospital of Yichang, Yichang, Hubei, China.
Huiling LiDepartment of Rheumatology and Immunology, The Traditional Chinese Medical Hospital of Hubei Province, Wuhan, Hubei, China.
Wenyu ZhouDepartment of Rheumatology and Immunology, Wuhan Fourth Hospital (Puai Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Tao ZhouDepartment of Rheumatology and Immunology, Wuhan Puren Hospital affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China.
Qin HuangDepartment of Nephrology and Rheumatology, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi, Hubei, China.
Aichun ChuDepartment of Prevention and Health Care, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Zachary BraunsteinDepartment of Medicine, Ohio State University, Columbus, OH, USA.
Xiaoquan RaoOregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, OR, USA.
Cong YeDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Lingli DongDepartment of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jingzhou Central Hospital · CNTongji Hospital · CNWuhan University · CNChina Three Gorges University · CNOregon Health & Science University · USWuhan Puai Hospital · CNXiangyang Central Hospital · CNHubei Provincial Hospital of Traditional Chinese Medicine · CNThe Central Hospital of Enshi Tujia and Miao Autonomous Prefecture · CNUnion Hospital · CNWuhan No.1 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19 remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases during the ongoing COVID-19 pandemic.

methodsWe did a multicentre retrospective study of patients with autoimmune rheumatic diseases in Hubei province, the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information, including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19.

findingsBetween March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included in the study. The overall rate of COVID-19 in patients with an autoimmune rheumatic disease in our study population was 0·43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019, and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio [OR] 2·68 [95% CI 1·14-6·27]; p=0·023). Patients with rheumatic disease who were taking hydroxychloroquine had a lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0·09 [95% CI 0·01-0·94]; p=0·044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1·04 [95%CI 1·01-1·06]; p=0·0081).

interpretationPatients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population.

fundingNational Natural Science Foundation of China and the Tongji Hospital Clinical Research Flagship Program.

Identifiers

PMID32838309
PMCPMC7333992
OpenAlexW3038582169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.